Skip to content

A comparative study on the efficacy and safety of cerebroprotein hydrolysate for injection (I) combined with cerebropeptide oral liquid in the treatment of children with temporary intellectual developmental disorders

A comparative study on the efficacy and safety of cerebroprotein hydrolysate for injection (I) combined with cerebropeptide oral liquid in the treatment of children with temporary intellectual developmental disorders

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063422
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-12-05
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporary intellectual developmental disability in children

Interventions

Cerebroprotein hydrolysate for injection (I) + brain peptide group:Cerebroprotein hydrolysate for injection (I) + brain polypeptide group: The use of cerebroprotein hydrolysate (I) for injection is 10
control group:with conventional basic treatment only

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.5 Years to 3 Years

Inclusion criteria

Inclusion criteria: 1. The subject's guardian voluntarily signed the informed consent; 2. Aged 6-36 months, regardless of gender; 3. Diagnosed as temporary intellectual developmental disorder (disease code 6A00.4 in ICD-11); 4. There is evidence of intellectual developmental disability, and the DQ value of the Gesell Developmental Diagnostic Scale test result is 25 <= DQ <= 70.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to cerebroprotein hydrolysate preparations for injection; 2. Those who have used neuroprotective drugs (such as mouse neurotrophic factor, ganglioside, etc.) within 14 days before enrollment or have a clear effect on promoting neurodevelopment; 3. Obvious abnormal posture or limb movement disorder, or diagnosed cerebral palsy; 4. Known to have other motor retardation/disorder diseases, unexplained motor, language or cognitive function regression/degenerative phenomena, autism spectrum disorders, musculoskeletal disorders, spinal cord disorders, peripheral nerve disorders, chromosomal disorders, genetic metabolic disorders, endocrine disorders, autoimmune disorders, CNS congenital malformations, other serious systemic disorders, hematologic disorders; 5. Patients with epileptiform discharge or epilepsy on EEG; 6. Those who have participated in clinical trials of other new drugs within the past 90 days; 7. Those who are considered unsuitable for participating in this experiment by the researchers.

Design outcomes

Primary

MeasureTime frame
Developmental Quotient (DQ) assessed by the modified Gesell Developmental Diagnostic Scale;

Secondary

MeasureTime frame
Infant-Junior High School Student Social Ability Scale (S-M);electroencephalogram (EEG);Head MRi;

Countries

China

Contacts

Public ContactWu De

The First Affiliated Hospital of Anhui Medical University

845177603@qq.com+86 13966730422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026